Impact of Cardiovascular Involvement on the Clinical Course of Paediatric Mitochondrial Disorders
Overview
Authors
Affiliations
Background: Primary mitochondrial disorders (PMD) are rare conditions resulting in progressive multi-organ failure. Cardiovascular involvement (CVI) has been reported in paediatric patients. However, its age-related prevalence, clinical presentation and prognostic impact are unresolved. We detailed CVI in a cohort of children diagnosed with PMD over two decades at a tertiary referral centre.
Results: We enrolled 86 PMD patients (M/F = 30/56; mean age 6.4 ± 8.58 years). CVI was detected in 31 patients (36%), with mean age at onset of 5.7 ± 7.8 years including the pre- and neonatal phase in 14, often representing the first sign of PMD (42% of those with CVI). Heart disease resulted more common in males and in children with specific aetiologies (Barth, TMEM70 and MELAS syndromes). Hypertrophic, non-compaction and dilated cardiomyopathies were the prevalent disorders, although pulmonary arterial hypertension was also found. Adverse cardiac events (heart failure, resuscitated cardiac arrest, ICD/PM implantation, sudden death) occurred in 19% of children with CVI over a follow-up period of 5.4 ± 4.3 years. All-cause mortality was higher in patients with CVI compared to those without CVI (45.1% vs 21.8%; p < 0.01); female sex, age at onset < 5 years, acute heart failure at presentation and diabetes also proved independent predictors of outcome.
Conclusion: Cardiovascular involvement occurred in over one-third of children diagnosed with PMD, often at a very early age, and was associated with adverse prognosis. Final outcome of PMD-related CVI was influenced by the specific underlying aetiology, suggesting the need for tailored management of heart failure and sudden death prevention.
Mitochondrial non-energetic function and embryonic cardiac development.
Shi J, Jin Y, Lin S, Li X, Zhang D, Wu J Front Cell Dev Biol. 2024; 12:1475603.
PMID: 39435335 PMC: 11491369. DOI: 10.3389/fcell.2024.1475603.
Variability of Clinical Phenotypes Caused by Isolated Defects of Mitochondrial ATP Synthase.
Tauchmannova K, Pecinova A, Houstek J, Mracek T Physiol Res. 2024; 73(Suppl 1):S243-S278.
PMID: 39016153 PMC: 11412354. DOI: 10.33549/physiolres.935407.
Luca A, Paduret I, Tarca V, David S, Mindru D, Rosu S Nutrients. 2023; 15(22).
PMID: 38004189 PMC: 10675151. DOI: 10.3390/nu15224795.
Finsterer J Radiol Cardiothorac Imaging. 2023; 5(4):e230144.
PMID: 37693190 PMC: 10485717. DOI: 10.1148/ryct.230144.
Recent Advances in Modeling Mitochondrial Cardiomyopathy Using Human Induced Pluripotent Stem Cells.
Pavez-Giani M, Cyganek L Front Cell Dev Biol. 2022; 9:800529.
PMID: 35083221 PMC: 8784695. DOI: 10.3389/fcell.2021.800529.